secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001104659-24-057782
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Q1 2024 net loss $4.2M; cash $19.5M; NXP800 Phase 1b data encouraging
------------------------------------------------------------------------------

- Net loss $4.2M in Q1 2024 vs $4.0M in Q1 2023; cash $19.5M (up from $19.1M in Dec 2023).
- NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer shows encouraging preliminary data; FDA Fast Track granted.
- NXP900 preclinical data at AACR: robust activity in NSCLC cell lines; synergy with alectinib and osimertinib.
- R&D expense $2.7M (+$0.3M YoY); G&A $1.7M flat; interest income $0.2M (vs $0.1M).
- Several clinical data updates expected in 2H 2024; cash runway estimated into 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924057782/0001104659-24-057782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924057782/tm2413597d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-057782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer